NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
    Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
    India

    Expert panel recommends emergency use authorization for Zydus's three-dose vaccine

    Written by Ramya Patelkhana
    August 20, 2021 | 07:41 pm 3 min read
    Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
    Credits
    ZyCoV-D: CDSCO’s SEC on COVID-19 gives its nod to Zydus Cadila's three-dose COVID-19 vaccine

    The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday. Once approved by the Drug Controller General of India (DCGI), ZyCoV-D will become the first-ever plasmid DNA vaccine in the world to be used against COVID-19. Here's more.

    Three-dose vaccine will be administered intradermally using a needle-free injector

    Zydus Cadila's ZyCoV-D is a three-dose vaccine and each dose is given 28 days apart—the second and third doses are administered 28 days and 56 days after the first dose, respectively. Moreover, the vaccine would be administered intradermally with the help of a needle-free injector. If approved for use by the DCGI, ZyCoV-D will be the second indigenous vaccine to be used in India.

    Zydus Cadila applied for EUA to ZyCoV-D on July 1

    To recall, Ahmedabad-based Zydus Cadila had applied for the EUA from the DCGI for its COVID-19 vaccine on July 1. Earlier on Thursday, the SEC on COVID-19 had deliberated on the pharma major's application and decided to recommend granting the EUA to its ZyCoV-D. The expert panel has further sent its recommendations to the national drugs regulator for final approval.

    India has so far approved five COVID-19 vaccines

    Once cleared for use, ZyCoV-D will become the second indigenous COVID-19 vaccine after Hyderabad-based Bharat Biotech's COVAXIN and the sixth vaccine to be approved in India. So far, India has authorized five vaccines: Covishield, COVAXIN, Sputnik V, Moderna's vaccine, and J&J's single-dose vaccine.

    ZyCoV-D works against Delta variant: Zydus Cadila

    According to Zydus Cadila, it has conducted the largest clinical trial for ZyCoV-D in the country in more than 50 centers so far. Notably, trials were also conducted in the 12-18 years age group. Apart from adolescents, the company is also planning to conduct trials on children aged above five years. Zydus Cadila claims its COVID-19 vaccine provides protection against the Delta variant, too.

    What is the needle-free injection system?

    As mentioned before, ZyCoV-D is an intradermal vaccine administered using a needle-free injection system, which may also reduce several post-immunization side-effects. Usually, the needle-free injection procedure involves accelerating a fluid jet to high speeds so that it penetrates between the layers of the skin (intradermal) through a specialized fine-diameter nozzle. To note, all the vaccines currently being used in India are administered intramuscularly.

    ZyCoV-D has 66% efficacy rate against symptomatic COVID-19 cases

    Zydus Cadila said ZyCoV-D is 66% effective against symptomatic COVID-19 cases and has shown a 100% efficacy rate against moderate cases. It can be stored at 2-8 degrees Celsius and remains stable even at 25 degrees Celsius for up to three months. ZyCoV-D has been developed by Zydus Cadila in collaboration with the Department of Biotechnology and the Indian Council of Medical Research (ICMR).

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Central Drugs Standard Control Organization (CDSCO)
    Drugs Controller General of India
    Zydus Cadila
    COVID-19
    COVID-19 Vaccine

    Central Drugs Standard Control Organization (CDSCO)

    J&J withdraws vaccine approval request in India, CDSCO says Johnson & Johnson
    Government expert panel recommends conducting trials on mixing Covishield, COVAXIN Christian Medical College
    Expert panel says no to Covovax's children trials in India Drugs Controller General of India
    COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel Vaccine

    Drugs Controller General of India

    India's drug regulator approves study on mixing Covishield, COVAXIN jabs World Health Organization
    India offered 7.5mn doses of Moderna vaccine under COVAX program COVID-19 Vaccine
    Hetero seeks Emergency Use Authorization for Molnupiravir in India Indian Council of Medical Research (ICMR)
    DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG Defence Research and Development Organisation (DRDO)

    Zydus Cadila

    Zydus Cadila COVID-19 vaccine may get emergency nod this week Mansukh Mandaviya
    Zydus vaccine for 12-18-year-olds from September, says expert panel chief Coronavirus
    Zydus applies for approval of its 3-dose, needle-free COVID-19 vaccine Drugs Controller General of India
    Zydus to seek approval for its COVID-19 vaccine next week India

    COVID-19

    Half of India's 87K breakthrough infections in Kerala, Centre says Kerala
    Centre prepared to tackle possible COVID-19 third wave: Anurag Thakur Himachal Pradesh
    Intel to give $250 to employees for taking COVID-19 vaccines Intel
    Convalescent plasma therapy doesn't stop COVID-19 progression: NIH Government of India

    COVID-19 Vaccine

    Schools may be closed if COVID-19 situation worsens: UP government Uttar Pradesh
    Pfizer, AstraZeneca vaccines less effective against Delta variant: Oxford study Pfizer
    COVID-19 booster shot will be recommended in India: ICMR-NIV chief World Health Organization
    COVID-19 vaccine for children likely by September, says ICMR-NIV chief Indian Council of Medical Research (ICMR)
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023